MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
MESOBLAST LTD
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026
$11.95−1.33 (-10.02%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
MESOBLAST LTD income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2026
- Gross margin
- 86.1%
- Operating margin
- –
- Net margin
- -47.8%
- Return on equity, FY2026
- –
Financial strength
- Current ratio
- 2.43
- Debt to equity
- –
- Debt to assets
- 16.8%
- Cash to current liabilities
- 126.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –